While we had net income for the year ended December 31, 2021 we have incurred an operating loss for the year ended December 31, 2022, Additionally, prior to 2021, we have incurred operating losses in ten of the previous twelve years and negative cash flow from operations in ten of the previous twelve years.
The Company is currently a party to an Amended and Restated Term Loan Credit Agreement, dated as of February 23, 2018, as amended December 27, 2019, by and between the Company and HCP-FVA, LLC ("HCP-FVA"), (the "Amended and Restated Loan Agreement"). In connection with the June Offering, we entered into a letter agreement with Hale Capital Partners, LP ("Hale Capital"), dated June 2, 2021 (the "Loan Extension Letter Agreement"), that provided for an extension of the maturity date on Hale Capital's portion of the outstanding indebtedness owed under the Amended and Restated Loan Agreement to June 30, 2023. The remaining principal amount outstanding, which was owed to other lenders, was repaid in full. On July 19, 2022, we entered into a letter agreement with Hale Capital (the "Second Loan Extension Letter Agreement"), that provided for a subsequent extension of the maturity date on the outstanding indebtedness owed under the Amended and Restated Loan Agreement from June 30, 2023 to December 31, 2023. See Note (9) Notes Payable for more information. On February 10, 2023, the Company entered into a letter agreement with Hale Capital to further extend the maturity date of the senior secured debt to June 30, 2024, as described in Note (19), Subsequent Events, to the consolidated financial statements. Also, as described further in Note (12) Series A Redeemable Convertible Preferred Stock, the effective date of the mandatory redemption right of the Company's Series A Redeemable Convertible Preferred Stock (the "Series A Preferred Stock") held by HCP-FVA and Hale Capital was extended from July 30, 2021 to July 30, 2023 pursuant to that certain Amendment No. 1 to the Amended and Restated Certificate of Designations, Preferences and Rights of Series A Convertible Preferred Stock of the Company, dated as of June 24, 2021 (as amended, the "Certificate of Designations"). On July 19, 2022, the Company and Hale Capital entered into a letter agreement pursuant to which Hale Capital agreed not to exercise or to permit the exercise of the mandatory redemption right of the Series A Preferred Stock on or prior to December 31, 2023 unless the redemption is in accordance with Section 8(e)(z) of the Certificate of Designations or in accordance with a Breach Event (as defined in the Certificate of Designations). On February 10, 2023, the Company entered into a letter agreement with Hale Capital to further extend the redemption date of the Series A Preferred Stock to June 30, 2024, as described in Note (19), Subsequent Events, to the consolidated financial statements. If such Series A Preferred Stock was redeemed at December 31, 2022, the Company would have been required to pay the holders of the Series A Preferred Stock $16.0 million.
As of December 31, 2022, we had a working capital deficiency of $0.3 million, which is inclusive of current deferred revenue of $3.7 million, and a stockholders' deficit of $16.4 million. Our cash and cash equivalents at December 31, 2022 was $2.0 million, a decrease of $1.2 million compared to December 31, 2021. Our operating cash outflows for the year ended December 31, 2022 and 2021 were $1.2 million, and $0.9 million, respectively. There is no assurance that we will be successful in executing our business plan either through generating sufficient revenue or continuing to reduce operating costs. The failure to execute our business plan would have a material adverse effect on our results of operations and or our ability to continue operations. In addition, to the extent that we continue to incur losses or want to expand our operations, we may need to seek additional financing. There can be no assurance that we will be able to obtain additional financing. Moreover, it is likely that the terms of the Amended and Restated Loan Agreement and Series A Preferred Stock will make it more difficult for us to obtain additional financing, and any additional financing could be dilutive to our stockholders.